NYSE · AZN
AstraZeneca PLC
Healthcare · Drug Manufacturers - General
$170.08▼ 1.15% ($1.98)at close
Pre-market$169.80▼ 0.16%4:10 AM ET
Valuation
Revenue & margin DCF
Verdict: fairly priced. Price between Bear and Base.
The price needs 3.2% revenue growth a year for 10 years. Our scenarios assume 4.1–7.2%.
That's below its past 4-year pace of 11.9%.
Value per share
Base case
$216.27
Price used $170.08 is 21% below this
USD · TTM ending Jun 30, 2026 · Price Oct 27, 8:00 PM UTC
Revenue each value needs
Revenue today $61.4B. The price needs $83.8B by 2036. Base case: $107B. At its recent pace: $189B. Bear to Bull: $92B to $123B.
Revenue today $61.4B. The price needs $83.8B by 2036. Base case: $107B. At its recent pace: $189B. Bear to Bull: $92B to $123B.
Revenue in 2036
today $61.4B
−$23.5Bless than the Base case
Value per share · Base case
$216.27
Price $170.08
21% below this
- 10-yr revenue CAGR
- 5.7%
- Ending operating margin
- 25.5%
- Discount rate
- 6.9%
USD · TTM ending Jun 30, 2026 · Price Oct 27, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 3.71% over the last year. Revenue grew 8.61% over the trailing twelve months. Operating margin moved from 20.04% to 22.77%. Free cash flow grew 6.79% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 22.77%. A decisive move in revenue — currently up 8.61% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization.
Market multiples
Stock splits
Every 2 shares became 1
Every 1 shares became 2
Every 1 shares became 3
Profitability & growth
Analyst consensus
20
Buy
15
Hold
6
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Oct 30, 2026
Q3 FY26 · EPS est $2.60 · Revenue est $16.0B
Same quarter, year over year
FY26 YTD +11.8%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $5.21 vs $4.66 · all 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- $9.16
- +11.4%
- FY24
- $8.22
- —
Q2 FY26
Reported Jul 27, 2026 · Latest
HoverTap a cell to inspect
Actual
$2.63
Estimate
$2.50
Year over year
+20.6%
Vs prior quarter
+1.9%
Institutional Sentiment
AstraZeneca PLC · AZN
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.